Sharemaestro company-news research for Precipio Inc (PRPO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest PRPO news and sentiment

Precipio Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score53Neutral is 50
Early balanced news score 26/100 evidence confidence 96% direct company focus 23 current stories across 11 publishers
Latest weekly closeUSD 28.85week of 28 Aug 2026
Main news subjectEarnings86/100 share of current news
News data statusHealthy37 duplicate stories removed

Current company news

Early balanced news score

23 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone61/100 Published 30-day score53/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? Zacks · 24 Aug 2026 16:37

What supports the score

Direct evidence

23 current stories are mapped specifically to PRPO.

Source breadth

The score uses 11 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.420.

Confidence

Confidence is 26/100, below the threshold for a firm score.

53/100
News scoreEarly balanced news score
26/100
Confidencethin evidence
96%/100
Company news23 company stories
79/100
Story agreement21/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
05 Aug: 1 stories08 Aug: 1 stories14 Aug: 4 stories15 Aug: 6 stories17 Aug: 3 stories20 Aug: 1 stories21 Aug: 2 stories23 Aug: 1 stories24 Aug: 3 stories 05 Aug: tone 50, 1 stories08 Aug: tone 50, 1 stories14 Aug: tone 49, 4 stories15 Aug: tone 49, 6 stories17 Aug: tone 51, 3 stories20 Aug: tone 57, 1 stories21 Aug: tone 73, 2 stories23 Aug: tone 50, 1 stories24 Aug: tone 69, 3 stories 95505
03 Aug18 Aug01 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence8
0.42 after freshness weighting
Source breadth100
11 independent publishers
Company relevance96
share tied directly to this company
Freshness12
recency-weighted evidence
Agreement79
how closely stories agree
Publisher mix88
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks10 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar 2026: close 26.5342, indexed 100.013 Mar 2026: close 26.86, indexed 101.220 Mar 2026: close 27.88, indexed 105.127 Mar 2026: close 25.97, indexed 97.903 Apr 2026: close 25.4, indexed 95.710 Apr 2026: close 27.25, indexed 102.717 Apr 2026: close 28.3, indexed 106.724 Apr 2026: close 27.995, indexed 105.501 May 2026: close 30.94, indexed 116.608 May 2026: close 29.81, indexed 112.315 May 2026: close 26.04, indexed 98.122 May 2026: close 23.8, indexed 89.729 May 2026: close 22.8, indexed 85.905 Jun 2026: close 23.49, indexed 88.512 Jun 2026: close 22.1, indexed 83.319 Jun 2026: close 22.45, indexed 84.626 Jun 2026: close 23.31, indexed 87.803 Jul 2026: close 25.26, indexed 95.210 Jul 2026: close 23.8, indexed 89.717 Jul 2026: close 24.64, indexed 92.924 Jul 2026: close 23.68, indexed 89.231 Jul 2026: close 21.65, indexed 81.607 Aug 2026: close 23.97, indexed 90.314 Aug 2026: close 23.5, indexed 88.621 Aug 2026: close 30.45, indexed 114.828 Aug 2026: close 28.85, indexed 108.7 26 Jun 2026: news score 50, close 23.31, 2 stories5003 Jul 2026: news score 51, close 25.26, 5 stories10 Jul 2026: news score 50, close 23.8, 5 stories5017 Jul 2026: news score 50, close 24.64, 12 stories24 Jul 2026: news score 50, close 23.68, 15 stories5031 Jul 2026: news score 50, close 21.65, 24 stories07 Aug 2026: news score 50, close 23.97, 28 stories5014 Aug 2026: news score 52, close 23.5, 32 stories21 Aug 2026: news score 54, close 30.45, 37 stories5428 Aug 2026: news score 54, close 28.85, 29 stories54 Price index 120.8 99.1 77.4 News score 100 50 0
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
26-week price+8.7%latest close 28.85
News score change+4first to latest comparable week
One-week response-5.3%Price reacting lower
Fair-value position+126.2%Materially above fair value
WeekNews scoreCloseWeekly move
28 Aug 202654USD 28.85-5.3%
21 Aug 202654USD 30.45+29.6%
14 Aug 202652USD 23.5-2.0%
07 Aug 202650USD 23.97+10.7%
31 Jul 202650USD 21.65-8.6%
24 Jul 202650USD 23.68-3.9%
17 Jul 202650USD 24.64+3.5%
10 Jul 202650USD 23.8-5.8%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings6417 stories · 74%
Market update505 stories · 22%
Balance sheet201 stories · 4%

Source mix

Where the evidence comes from

88/100 independence
Zacks652 stories · 9%
GuruFocus412 stories · 9%
vinanet.vn562 stories · 9%
Quiver Quantitative562 stories · 9%
Stock Titan492 stories · 9%
Stock Traders Daily502 stories · 9%
dars.gov.et791 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences14Earnings13Financial Markets6Finance5Earnings News1

Earlier readings

How the score has changed

30 comparable readings · 68 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+350 to 53 · Broadly stable
Observed range50–5650 is the neutral baseline
Evidence depth23stories at latest stored reading · +22
Confidence24/100Provisional · +24
25 Jun50 neutral01 Sep 12:18
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
01 Sep 12:1853-324/100 (-13)23 (-14)Provisional
24 Aug 23:5956+237/100 (+2)37 (+1)Measured
23 Aug 23:5954+035/100 (-5)36 (-1)Measured
21 Aug 23:5954+340/100 (+3)37 (+1)Measured
20 Aug 23:5951+037/100 (-6)36 (+1)Measured
17 Aug 23:5951+043/100 (-1)35 (+2)Measured
15 Aug 23:5951-144/100 (+2)33 (+1)Measured
14 Aug 23:5952+242/100 (+22)32 (+3)Measured

Source headlines

The news behind the score

Showing 1-23 of 23

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
ZacksDirect company coverageStored article

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

This article compares two specialty cancer diagnostics companies, Precipio, Inc. (PRPO) and Biodesix, Inc. (BDSX), to determine which stock is a better investment. While both operate in cancer diagnostics, they have different business focuses and financial profiles. The analysis concludes that PRPO is the better buy due to its attractive valuation, expanding product commercialization, integrated pathology-product model, and improving financial sustainability.

EarningsFinancial MarketsLife Sciences
Published
24 Aug 2026 16:37
News subject
Earnings
Why this score
Positive valuation view
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.8d old
Duplicates
2 consolidated
#279Tone
dars.gov.etDirect company coverageScored from headline

Precipio (PRPO) Results Versus Estimates: The Report Supplies Updated Headline Figures in the Available Record; Price Reaction: The Stock Ends Down 1.41% for the Current Session - Earnings Beat Streak

Published
24 Aug 2026 15:30
News subject
Earnings
Why this score
Beat expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 64/100
30-day weight
19.2% of the score · 7.9d old
Duplicates
1 consolidated
#4—Not directional
Quiver QuantitativeDirect company coverageScored from headline

PRPO | Precipio, Inc. Common Stock Financials - Revenue Breakdown

Published
23 Aug 2026 02:14
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 9.4d old
Duplicates
1 consolidated
#574Tone
ZacksDirect company coverageStored article

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

Precipio (PRPO) shares gained significantly following strong Q2 2026 earnings, with net sales up 24.7% year-over-year to $7 million. Despite a net loss, the company saw substantial growth in service and product revenues, improved gross profit and adjusted EBITDA, and generated positive operating cash flow. Management highlighted record quarterly revenue and an expanding customer base, expecting continued growth.

EarningsLife Sciences
Published
21 Aug 2026 15:31
News subject
Earnings
Why this score
Improving financial comparison, Operating growth
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 54/100
30-day weight
14.1% of the score · 10.9d old
Duplicates
3 consolidated
#861Tone
Investing.com South AfricaDirect company coverageStored article

Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

Precipio Diagnostics reported record Q2 2025 revenue of $7.0 million, a 22.8% increase year-over-year, marking the first time the company exceeded $7 million in a quarter. The company achieved positive adjusted EBITDA of $400,000 and generated $700,000 in operating cash flow without a capital raise, demonstrating a successful shift to profitable growth driven by both pathology and record product sales. Management expressed optimism for continued revenue growth and commercial pipeline conversion in the second half of 2026.

EarningsLife Sciences
Published
17 Aug 2026 22:12
News subject
Earnings
Why this score
Operating growth
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
6.2% of the score · 14.6d old
Duplicates
1 consolidated
#941Tone
GuruFocusDirect company coverageStored article

PRPO Looks 118.2% Overvalued on GF Value™

Precipio Inc (PRPO) reported increased Q2 2026 revenue and adjusted EBITDA, signaling operational improvements, yet its stock appears significantly overvalued by the GF Value™ metric. The company's GF Score™ of 51/100 reflects strong momentum but weaknesses in growth, profitability, and valuation, with insider selling and a guru investor trimming positions suggesting caution. Investors are advised to carefully consider these factors due to the stock's speculative nature and ongoing unprofitability.

EarningsFinancial MarketsLife Sciences
Published
17 Aug 2026 08:41
News subject
Earnings
Why this score
Negative valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 38/100
30-day weight
5.6% of the score · 15.2d old
Duplicates
1 consolidated
#10—Not directional
seekingalpha.comDirect company coverageStored article

Precipio reports Q2 results

* Precipio press release [https://seekingalpha.com/pr/20620078-precipio-announces-q2minus-2026-financial-results] (PRPO [https://seekingalpha.com/symbol/PRPO]): Q2 Revenue of $7M (+22.8% Y/Y). * Adjusted EBITDA – $0.4M vs. $(0.2)M in Q1-2026. * Cash flow - Cash Flow generated from operations was $0.7M in Q2-2026; total increase in cash was $0.5 million, resulting in an end of quarter cash balance exceeding $3M, vs $1.1M in Q2-2025. MORE ON PRECIPIO * Historical earnings data for Precipio [https://seekingalpha.com/symbol/PRPO/earnings] * Financial information for Precipio [https://seekingalpha.

EarningsEarnings News
Published
17 Aug 2026 07:40
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.2d old
Duplicates
1 consolidated
#11—Not directional
MobyDirect company coverageScored from headline

Precipio, Inc. Q2 2026 Earnings Call Summary

Published
15 Aug 2026 12:30
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.0d old
Duplicates
1 consolidated
#12—Not directional
Stock Traders DailyDirect company coverageStored article

(PRPO) Risk Channels and Responsive Allocation

This article analyzes Precipio Inc. (NASDAQ: PRPO), identifying a weak near-term sentiment despite potential long-term strength. It highlights an exceptional 71.3:1 risk-reward setup targeting a 19.1% gain with only 0.3% risk. The analysis provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.

FinanceFinancial MarketsLife Sciences
Published
15 Aug 2026 09:41
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.1d old
Duplicates
1 consolidated
#1336Tone
MoomooDirect company coverageStored article

Precipio 2Q Loss $200,000 >PRPO

Precipio reported a second-quarter loss of $200,000, which translates to a loss of one cent per share. This financial update includes the company's net loss and per-share loss for the quarter.

EarningsLife Sciences
Published
15 Aug 2026 06:41
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 41/100
30-day weight
3.9% of the score · 17.2d old
Duplicates
1 consolidated
#1463Tone
The Manila TimesDirect company coverageStored article

Precipio Announces Q2-2026 Financial Results

Precipio, Inc. (NASDAQ: PRPO) announced strong financial results for Q2-2026, with record quarterly revenue of $7.0 million, a 22% year-over-year increase from Q2-2025. The company also returned to positive Adjusted EBITDA of $0.4 million and significantly strengthened its cash position to over $3 million without a financing event. These results reflect a healthy recovery and continued momentum in the business, driven by customer growth and increased product revenues.

EarningsLife Sciences
Published
15 Aug 2026 06:10
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 40/100
30-day weight
4.3% of the score · 17.3d old
Duplicates
4 consolidated
#15—Not directional
TradingViewDirect company coverageStored article

Precipio, Inc. 2026: Revenue $7.02M, EPS ($0.12) — 10-Q Summary

Precipio, Inc. (PRPO) reported its second-quarter 2026 results, showing a revenue increase to $7.02 million from $5.63 million in the prior year, a 24.7% rise. Despite the revenue growth, the company recorded a net loss of ($219K) and a diluted loss per share of ($0.12), compared to a net income of $74K and EPS of $0.05 in the previous year. The growth was driven by higher case volumes and increased product sales, mainly from pathology service volume, although the average price per case declined due to a shift towards lower-priced products.

EarningsFinanceLife Sciences
Published
15 Aug 2026 02:41
News subject
Earnings
Why this score
Improving financial comparison, Operating growth
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.4d old
Duplicates
1 consolidated
#1641Tone
GuruFocusDirect company coverageStored article

Is Precipio Inc (PRPO) Overvalued Despite Q2 Revenue of $7M? GF Score: 51/100, Valuation Discrepancy of 118.4%

Precipio Inc (PRPO) reported record Q2 2026 revenue of $7.0 million, returning to positive Adjusted EBITDA, and strengthening its cash position. Despite this operational recovery, GuruFocus assesses PRPO as significantly overvalued with a GF Score of 51/100 and a valuation discrepancy of 118.4%. The company faces challenges with its financial strength, profitability, growth, and predictability ranks, and recent insider selling further suggests caution for investors.

EarningsFinanceLife Sciences
Published
15 Aug 2026 01:10
News subject
Earnings
Why this score
Negative valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
4.1% of the score · 17.5d old
Duplicates
1 consolidated
#1757Tone
Quiver QuantitativeDirect company coverageScored from headline

Precipio Q2 Revenue Hits Record $7.0 Million, Up 22% Year Over Year

Published
14 Aug 2026 21:35
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 32/100
30-day weight
2.4% of the score · 17.6d old
Duplicates
1 consolidated
#1888Tone
Stock TitanDirect company coverageStored article

Precipio (PRPO) hits record Q2 revenue above $7M and returns to positive Adjusted EBITDA

Precipio, Inc. (PRPO) announced record Q2 2026 revenue exceeding $7 million, driven by continued customer growth and a 21% increase in product revenues from the previous high in Q4 2025. The company also returned to positive Adjusted EBITDA of $0.4 million, compared to a negative figure in Q2 2025, and increased its cash balance to over $3 million without external financing. Despite a GAAP net loss of $0.2 million, management highlighted operational strength and positive momentum, planning a shareholder call on August 17, 2026, for further discussion.

EarningsFinanceLife Sciences
Published
14 Aug 2026 21:40
News subject
Earnings
Why this score
Beat expectations, Improving financial comparison, Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 68/100
30-day weight
8.9% of the score · 17.6d old
Duplicates
3 consolidated
#1920Tone
Stock TitanDirect company coverageScored from headline

Precipio, Inc. (PRPO) grows Q2 2026 revenue 24% amid going concern warning

Published
14 Aug 2026 20:05
News subject
Balance sheet
Why this score
Balance-sheet distress
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 61/100
30-day weight
11.7% of the score · 17.7d old
Duplicates
1 consolidated
#2040Tone
scanx.tradeDirect company coverageStored article

Precipio Q2 Results: EPS turns to loss of $(0.12), sales up 24%

Precipio reported a Q2 EPS loss of $(0.12), a 340% decrease from the previous year's profit, indicating significant margin compression. Despite this, the company achieved strong top-line growth with sales increasing 24.18% to $7.021 million. This divergence suggests that while revenue expanded, operating costs grew at a faster rate, leading to a net loss for the quarter.

EarningsLife Sciences
Published
14 Aug 2026 20:40
News subject
Earnings
Why this score
Deteriorating financial comparison
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 38/100
30-day weight
4.1% of the score · 17.7d old
Duplicates
1 consolidated
#21—Not directional
TradingKeyDirect company coverageStored article

Precipio Inc (PRPO) Stock News Today

This article provides current stock news for Precipio Inc (PRPO). As of the article's publication, PRPO's stock is trading at $23.970, up +2.17%, with a market cap of 42.75M USD. The article notes that more news is expected soon regarding the company.

EarningsFinancial MarketsLife Sciences
Published
08 Aug 2026 03:39
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 24.4d old
Duplicates
1 consolidated
#22—Not directional
Stock Traders DailyDirect company coverageStored article

(PRPO) Movement as an Input in Quant Signal Sets

This article analyzes Precipio Inc. (NASDAQ: PRPO) using AI models to generate trading strategies across different risk profiles. Key findings indicate divergent sentiment, suggesting choppy conditions, and highlights support and resistance levels. The analysis provides specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.

Financial MarketsLife Sciences
Published
05 Aug 2026 00:41
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 27.5d old
Duplicates
1 consolidated
#23—Not directional
The Globe and MailDirect company coverageStored article

Precipio Schedules Q2 2026 Shareholder Update Call

Precipio (PRPO) announced it will host its Q2 2026 shareholder update call on August 17, 2026, at 5:00 p.m. ET to discuss performance in its cancer diagnostics businesses. CEO Ilan Danieli will provide remarks on progress and engage in a live Q&A session. TipRanks' AI Analyst, Spark, rates PRPO as Neutral, citing improving financials but noting negative net income and mixed technical positioning.

EarningsFinanceFinancial MarketsLife Sciences
Published
02 Aug 2026 20:10
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 29.7d old
Duplicates
3 consolidated

Earlier company news

PRPO news archive

Showing 1-30 of 34 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Aug 01 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Financial Health: Profitability & Balance Sheet Analysis

Precipio Inc (PRPO) has a weak financial status with a score of 4.51, ranking 199 out of 200 in its industry. Despite this, the company reported a significant year-over-year revenue increase of 36.15% and a net profit increase of 63.24% in its latest quarter. Key financial metrics such as cash and cash equivalents, operating profit, and free cash flow were not disclosed, indicating a lack of transparency or available data.

EarningsLife Sciences
Published
1 Aug 2026 05:43
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 01 2026
Stock TitanArchivedNeutral tone

Precipio (NASDAQ: PRPO) plans Q2 2026 shareholder call with live Q&A

Precipio, Inc. (NASDAQ: PRPO) announced it will host a Q2-2026 shareholder update call on August 17, 2026, at 5:00 PM ET. The call will cover updates on the company's core businesses and include a live moderated Q&A session. CEO Ilan Danieli expressed optimism about progress in customer acquisition, pipeline expansion, and business growth, which will be reflected in the upcoming Q2 results.

EarningsFinanceLife Sciences
Published
1 Aug 2026 04:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Aug 01 2026
scanx.tradeArchivedNeutral tone

Precipio Inc. Q2 Results: Shareholder update call set for August 17

Precipio Inc. has scheduled its Q2-2026 shareholder update call for August 17, 2026, at 5:00 PM ET. CEO Ilan Danieli will discuss core business updates and progress in customer acquisition and pipeline expansion. Investors can participate in a live Q&A session or submit questions in advance, with a replay available online shortly after the call.

EarningsLife Sciences
Published
1 Aug 2026 02:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Precipio Inc (PRPO), detailing its current risk score of 2.96 within the Healthcare Equipment & Supplies industry. It highlights the company's beta value of 1.33, indicating higher volatility compared to the S&P 500. The assessment also covers various metrics including VaR, maximum drawdown, volatility, return performance, Sharpe Ratio, skewness, and liquidity.

Financial Markets
Published
31 Jul 2026 06:11
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 31 2026
TradingKeyArchivedLegacy headline · tone unscoredLegacy source lookup

PRPO|Precipio Inc|Price:21.690|Chg%:-0.980

Published
31 Jul 2026 04:10
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated
Jul 29 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Institutional Confidence

This article analyzes the institutional confidence score for Precipio Inc (PRPO), which stands at 3.00, ranking 130 out of 199 in its industry. The institutional shareholding proportion is 19.15%, showing a slight decrease. James Simons is identified as the largest institutional shareholder, with other significant holders like AMH Equity, Ltd. and Topline Capital Management, LLC also listed.

Financial Markets
Published
29 Jul 2026 16:40
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 28 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Precipio Inc (PRPO), noting its current valuation score of 8.08 within the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -50.70, which is significantly below its recent high but above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Precipio Inc.

EarningsFinancial MarketsLife Sciences
Published
28 Jul 2026 04:09
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Precipio Inc (PRPO) as of April 6, 2026. The data categorizes revenue by business segment, with third-party payers and Medicare contributing the largest proportions at 48.26% and 39.65% respectively. The report also lists smaller contributions from other categories such as contract diagnostics, Medicaid, and self-pay.

EarningsLife Sciences
Published
27 Jul 2026 15:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNegative tone

PRPO|Precipio Inc|Price:23.490|Chg%:-0.190

Precipio Inc (PRPO) has a TradingKey Stock Score indicating stable fundamentals, significant growth potential, and high institutional ownership, despite an expected medium-term stock price decline. The biotechnology company focuses on cancer diagnostics with technologies like HemeScreen and IV-Cell, showing strong revenue growth and increased investor interest. Its valuation is considered fair within the Healthcare Equipment & Supplies industry.

EarningsFinancial MarketsLife Sciences
Published
27 Jul 2026 15:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
2 consolidated
Jul 27 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Precipio Inc (PRPO), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, including hedge funds, individual investors, and investment advisors, alongside historical institutional shareholding data and recent shareholder activity. The information is current as of recent dates in 2025 and 2026, offering insights into the company's ownership distribution.

Financial Markets
Published
27 Jul 2026 03:39
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Precipio Inc (PRPO), covering operating, investing, and financing activities. It also includes an FAQ section explaining different types of cash flow and Precipio Inc's performance in each category, highlighting figures like operating cash flow of 685.00K in fiscal 2025 and capital expenditures of 326.00K in the most recent quarter. The company’s free cash flow in the latest quarter was 359.00K.

EarningsFinanceFinancial MarketsLife Sciences
Published
26 Jul 2026 16:12
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedNeutral tone

Precipio Inc (PRPO) Income Statement

This article provides a detailed quarterly and annual income statement for Precipio Inc (PRPO), offering insights into its revenue, operating expenses, net income, and earnings per share. It covers financial data extending from FY2012Q1 through FY2026Q1, highlighting key metrics like total revenue, cost of revenue, operating profit, and net income attributable to common shareholders. The document also includes an FAQ section explaining how to read an income statement and defining important financial terms for investors.

EarningsFinance
Published
26 Jul 2026 15:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 26 2026
TradingKeyArchivedPositive tone

Precipio Inc (PRPO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Precipio Inc (PRPO), detailing future EPS and revenue growth estimates. It includes a snapshot of PRPO's stock performance, market capitalization, and a breakdown of TradingKey's stock score components such as financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The page also presents a peer comparison with other medical technology companies.

EarningsFinancial MarketsLife Sciences
Published
26 Jul 2026 04:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 25 2026
MoomooArchivedNeutral tone

Precipio Announces Q1-2026 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will cover the company's core businesses and include a moderated live Q&A session for the first time, demonstrating Precipio's commitment to transparency and shareholder engagement. Investors can pre-submit questions via email or ask them live during the call.

EarningsFinanceLife Sciences
Published
25 Jul 2026 02:41
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 25 2026
TradingViewArchivedPositive tone

Precipio, Inc. Revenue Breakdown – NASDAQ:PRPO

This article provides a brief overview of Precipio, Inc.'s revenue breakdown. The company's primary revenue contribution comes from the United States, generating $24.05 million last year, up from $18.53 million the previous year. The data presented focuses on top segments and regional performance.

EarningsFinanceFinancial MarketsLife Sciences
Published
25 Jul 2026 02:41
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 23 2026
Stock Traders DailyArchivedNeutral tone

Liquidity Mapping Around (PRPO) Price Events

Quantitative analysis for Precipio Inc. (NASDAQ: PRPO) indicates weak near and mid-term sentiment, despite a strong long-term outlook. The report highlights elevated downside risk due to a lack of additional long-term support signals and provides institutional trading strategies for long, breakout, and short positions based on AI-generated signals.

Financial MarketsLife Sciences
Published
23 Jul 2026 20:46
Catalyst
Guidance
Coverage
Direct company
Duplicates
1 consolidated
Jul 17 2026
Investing.com NigeriaArchivedNeutral tone

Form 4 Precipio Inc For: 16 July By Investing.com

This article announces a Form 4 filing for Precipio Inc., dated July 16, as reported by Investing.com. It is a brief notification with a link to regulatory details. The content also showcases various market data and other news headlines common to the Investing.com platform.

Financial Markets
Published
17 Jul 2026 12:39
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock TitanArchivedNeutral tone

Precipio, Inc. (PRPO) director takes stock in lieu of cash pay

Precipio, Inc. Director David Seth Cohen received 520 shares of common stock on July 15, 2026, as compensation for his Q2-26 board service, totaling $13K. This grant, valued at $25.24 per share, was issued in lieu of a cash payment and increased his direct holdings to 55,199 shares. The transaction was reported in a Form 4 filing and underscores a method of director compensation through equity.

FinanceFinancial MarketsLife Sciences
Published
16 Jul 2026 21:10
Catalyst
Balance sheet
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock TitanArchivedNeutral tone

Precipio (PRPO) director receives 108-share stock grant for Q2-26 service

Precipio, Inc. director Christina Rizopoulos received a grant of 108 shares of common stock on July 15, 2026, as compensation for her Board service during Q2-26. The shares were valued at $25.24 each and were issued in lieu of a cash payment. Following this transaction, Ms. Rizopoulos directly holds 5,628 Precipio common shares.

EarningsFinance
Published
16 Jul 2026 21:10
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock TitanArchivedNeutral tone

Precipio, Inc. (PRPO) director gets 416-share stock grant for Q2 board fees

Precipio, Inc. director Jeffrey Cossman received a grant of 416 shares of common stock on July 15, 2026, as compensation for his Q2-26 Board of Directors service. This equity award, valued at $25.24 per share, increased his direct holdings to 16,549 common shares. The transaction was reported in a Form 4 filing and represents compensation in stock rather than cash for board service.

Finance
Published
16 Jul 2026 21:10
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 16 2026
Stock Traders DailyArchivedLegacy headline · tone unscoredLegacy source lookup

Liquidity Mapping Around (PRPO) Price Events

Published
16 Jul 2026 17:48
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

1 not scored

A news provider linked these stories to PRPO, but the headline and available text are not mainly about Precipio Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of PRPO sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context